more_reports

Dr. Douglas Loe

Leede Jones Gable

Image: Dr. Douglas Loe

Douglas Loe, managing director and analyst at Leede Jones Gable, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors. Loe has been recognized as one of Canada's top healthcare analysts by the StarMine Analysts Awards, based on the quality of his recommendations to institutional investors. He holds a Ph.D. in biochemistry.

Recent Articles

Analyst Encouraged by ON Gov's Decision To Sustain Fees 04/02/2024

CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note.

Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says 03/26/2024

K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note.


Recent Quotes

"Updates on Alzheimer's by three biopharmas are pertinent to PMN."

— Dr. Douglas Loe, Leede Jones Gable (1/27/23)
more >

more quotes

"AGN plans to initiate a Phase 2b trial of ifenprodil in chronic cough."

— Dr. Douglas Loe, Leede Jones Gable (1/13/23)
more >

"We expect PMN to commence formal Phase 1 testing later this year."

— Dr. Douglas Loe, Leede Jones Gable (1/6/23)
more >

"Data presented by peers at the CTAD conference are relevant to PMN."

— Dr. Douglas Loe, Leede Jones Gable (12/1/22)
more >

"RHT added 50 new nursing home clients in Florida to its network."

— Dr. Douglas Loe, Leede Jones Gable (11/4/22)
more >

"PMN peer, Eisai, reported positive Phase 3 Alzheimer's disease data."

— Dr. Douglas Loe, Leede Jones Gable (9/30/22)
more >

"We are positive about PMN's PMN-310 possibly mitigating AD progression."

— Dr. Douglas Loe, Leede Jones Gable (9/28/22)
more >

"Experiments showed that PMN's PMN310 has a unique binding profile."

— Dr. Douglas Loe, Leede Jones Gable (8/5/22)
more >

"PMN's PMN310 could benefit from favorable FDA review of lecanemab."

— Dr. Douglas Loe, Leede Jones Gable (7/6/22)
more >

fewer comments


Due to permission requirements, not all quotes are shown.